I forbindelse med kongressen vil EACPT uddele en lifetime achievement award:
EACPT Prize 2017 for Lifetime Achievement in Clinical Pharmacology
The EACPT Lifetime Achievement Award is made for significant achievement, both for the benefit of science and also for the benefit and health of clinical pharmacology, over a whole working life. The EACPT Executive Committee was delighted that there were seven excellent proposals for this prestigious award made prior to the deadline of October 31st 2016, indicating the strength of our discipline across Europe.
Thank you to all EACPT Councillors for taking the time to consider the applications and cast their votes. I am delighted to be able to announce that the winner of the award for 2017 was
Professor Pertti Neuvonen
He will be invited to receive his award at the next EACPT Congress being held in Prague from the 23rd to 27th June. The award ceremony will be held at 16.00 on Saturday 24th June 2017. He will also deliver a Plenary lecture entitled
'Steps towards safe and predictable drug treatment - picks from five decades'
On behalf of the whole European clinical pharmacology community we would like to extend our congratulations to Professor Neuvonen and look forward to welcoming him to Prague.
Professor (emer.) Pertti J. Neuvonen has been listed for years as an ISI Highly Cited Researcher (pharmacology, Thomson Reuters), and he is one of the most cited clinical pharmacologists in the world, with over 20,000 citations. He has authored over 500 original articles and several reviews. Of the originals, 92 have been published in the Clinical Pharmacology & Therapeutics. He has supervised about 50 Doctoral (PhD) thesis projects. His research focuses on drug safety and individual variability in drug response, particularly on drug interactions and their mechanisms.
Since 1970, Neuvonen´s research group has found more than 200 previously unrecognized, clinically important drug-drug interactions and several significant food-drug interactions. Furthermore, his group demonstrated, already in the 1980-90s, the efficacy of activated charcoal as gastric decontaminator, compared with induced emesis and gastric lavage. The drug interaction studies in humans were deepened by in vitro studies to explore mechanism, predictability and avoidance of the interactions. His group observed that inhibition and induction of CYP3A4/5-enzyme could cause over 10-fold changes in exposure to several drugs (midazolam, triazolam, buspirone, felodipine, simvastatin, lovastatin). Furthermore, his group discovered among generally used drugs many previously unrecognized inhibitors of drug metabolism (itraconazole: CYP3A4; gemfibrozil and clopidogrel: CYP2C8) and unexpected victim substrates (tizanidine: CYP1A2; cerivastatin, repaglinide, pioglitazone, rosiglitazone, loperamide, montelukast: CYP2C8). In addition to drug metabolizing enzymes, also membrane transporters (e.g., OATP1B1, P-glycoprotein, BCRP), and their pharmacogenetics and interactions were found to affect pharmacokinetics (e.g., statins) and drug response. Many of the original findings made by Neuvonen and his research groups have been adopted into textbooks, guidelines (e.g., FDA) and product information texts.
Pertti Neuvonen was born in Kirvu (Finland) on 25. August 1943. He is married and has five adult children. He studied medicine at the University of Helsinki between 1964 and 1970, and he defended his doctoral thesis at this University in 1971. From 1971 to 1972, he was as a fellow of the Alexander von Humboldt-Foundation in Hannover Medical School (Germany). From 1972-1985, he was Senior Lecturer/Assistant Professor/Consultant of Clinical Pharmacology, and from 1986-1988 Acting Professor and Head Physician of Clinical Pharmacology at University of Helsinki and University Central Hospital, including the National Poison Information Centre. Between 1988 and 1991, he was Professor and Chairman of Pharmacology at University of Turku. From 1992 to 2011, he was Professor and Head of Clinical Pharmacology at University of Helsinki and University Central Hospital. After his retirement in 2011, he continues studies at the Department of Clinical Pharmacology as a free researcher. In 2011, he received the BCPT Nordic Prize in Basic & Clinical Pharmacology & Toxicology, and the Medal of the FDA Office of Clinical Pharmacology.
I 2019 bliver kongressen afholdt i Stockholm, Sverige og i 2021 bliver det Athen, Grækenland.
Alle kongresser afholdes i slutningen af juni måned.